To assess the impact of highly active antiretroviral therapy (HAART) on rates of change of antiretroviral treatment among patients co-infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) in the Australian HIV Observational Database (AHOD).
The use of highly active antiretroviral therapy (HAART) in Australia since 1996 has dramatically reduced the morbidity and mortality of patients with HIV [1, 2] . As the survival of HIV-infected patients continues to improve, and despite the obvious success of HAART, the necessity to continue therapy long term introduces other concerns, such as treatment-related toxicity and the management of comorbid conditions such as chronic viral hepatitis.
HIV is known to impact on the natural history of hepatitis B virus (HBV) and hepatitis C virus (HCV) disease. There has been evidence of higher rates of chronic HBV infection among HIV/HBV co-infected patients and higher HCV viral loads among those with HIV/HCV co-infection [3] . However, the impact of HBV and HCV on HIV remains ambiguous. Several studies have shown no impact of HBV or HCV co-infection on HIV disease progression [4, 5] , while others have shown accelerated HIV disease progression [6, 7] . Although there has been a slightly poorer CD4 count response in HIV/HCV co-infected patients [4, 8] , the impact of HAART on disease progression among patients coinfected with HBV and/or HCV remains relatively uncertain, particularly in the presence of treatment-related toxicities.
Hepatotoxicity associated with antiretroviral use has been shown in several studies to be more common in HIV-infected patients co-infected with HCV or HBV, particularly after initiating antiretroviral treatment [9, 10] . The protease inhibitor (PI) ritonavir and, more recently, nonnucleoside reverse transcriptase inhibitors (NNRTIs), including nevirapine and efavirenz, have been associated with hepatotoxicity [10] . However, others have found no association between the use of NNRTIs and hepatotoxicity [11] .
The aim of the present study was to assess the impact of HAART on rates of change of antiretroviral treatment among patients co-infected with HBV and/or HCV in the Australian HIV Observational Database (AHOD). In a previous study [12] , we demonstrated the use of rates of change of antiretroviral therapy to be a useful mid-range surrogate marker of disease progression, and to be more long range than conventional markers such as CD4 count and HIV viral load, but earlier than clinical AIDS-defining illness or death. This may be a good endpoint for examining the response to HAART in co-infected patients, in whom not only would HIV disease progression be expected to lead to increased rates of antiretroviral treatment change, but also significant liver toxicity to treatment would be expected to lead to increased rates of antiretroviral treatment change.
We also assessed the durability of the first HAART regimen, and the durability of HAART regimens including NNRTIs, which have been associated with liver toxicity.
Methods

Patients and data collection
The Australian HIV Observational Database collects data from 27 sites throughout Australia, including hospitals, sexual health clinics and general practitioners. Data are transferred electronically to the National Centre in HIV Epidemiology and Clinical Research (NCHECR) every 6 months. The following core data variables are collected: sex, date of birth, date of first positive HIV test result, date of most recent visit, HIV exposure category, HBV status, HCV status, CD4 and CD8 T-lymphocyte counts, HIV viral load counts, antiretroviral and opportunistic infection prophylaxis treatments, including start and stop dates, and AIDS-defining illnesses.
To be included in the present study, patients in the AHOD had to meet the following requirements: (1) initiation of HAART, defined as a combination of at least three antiretroviral agents, after 1 January 1997; (2) recorded test results for both HCV antibodies and HBV surface antigen (HBsAg); and (3) follow-up of at least 3 months from baseline, defined as the date the patient commenced HAART.
Definition of HBV and HCV serological categories
HBV infection was defined as a positive HBV surface antigen (HBsAg) test, and HCV infection as a positive anti-HCV antibody test. No distinction was made between patients being tested for hepatitis before and after initiation of HAART. Co-infection status was classified as follows: HBV and HCV negative; HBV positive only; HCV positive only; and co-infection with HBV and HCV.
Definition of combination change
An antiretroviral treatment change was defined as any change to a combination, including adding or dropping treatments, or reinitiating treatments previously received. In this definition, a treatment interruption of greater than 7 days was also considered a change.
Statistical analyses
For each patient, data were censored at the last date of follow-up, defined as the most recent of the following dates: most recent visit date, date of CD4 or viral load count, or date on which antiretroviral therapy started or stopped. Individual person-years of follow-up were calculated as the time between baseline (initiation of HAART) and the date of last follow-up. Rate of change of antiretroviral treatment was calculated as the number of combination changes over the person-years of follow-up.
The effect of hepatitis co-infection on the rate of antiretroviral treatment change after commencing HAART was assessed using a random-effect Poisson regression model, which allowed for the repeated-event nature of the data [13] . The effect of hepatitis co-infection on time to changing the first HAART combination was assessed with Kaplan-Meier survival curves and Cox proportional hazard models of time to change of first HAART combination.
Covariates tested for inclusion in multivariate models were sex, age group, HIV exposure category, viral load at baseline, CD4 cell count at baseline, AIDS-defining illness prior to baseline, antiretroviral therapy prior to baseline (none, mono or double), treatment class and calendar year. Nominal covariates were tested using w 2 tests for heterogeneity and ordinal covariates using tests for trend. Missing values were not included when testing ordinal covariates. Multivariate models were obtained using forward selection techniques. In addition, the association between hepatitis coinfection and time to stopping nevirapine or efavirenz was examined with Kaplan-Meier survival curves and the Wilcoxon test statistic.
All statistical analyses were performed using STATA 8.0 [14] . 
Results
By
Rate of change of antiretroviral treatment
The overall mean rate of treatment change after initiating HAART was 0.73 [95% confidence interval (CI): 0.70-0.77] per year for those without HBV/HCV co-infection, 0.71 (95% CI: 0.58-0.86) per year for those with HBV, and 0.83 Table 1 Patient characteristics by hepatitis B and C virus status Co Rate of change of antiretroviral treatment after commencing HAART was not associated with co-infection status (P 5 0.40). Table 2 presents factors associated with the rate of treatment change. In univariate analysis, rates of change were significantly associated with sex (P 5 0.043), AIDS-defining illness prior to initiating HAART (Po0.001), and exposure to antiretroviral therapy prior to commencing HAART (Po0.001). Antiretroviral treatment class was also found to be associated with the rate of treatment change (Po0.001), as well as the calendar year (Po0.001). Age, HIV exposure category, CD4 at baseline and RNA at baseline were not significantly associated with rate of treatment change. In multivariate analysis, AIDS-defining illness [incidence rate ratio (IRR) 5 1.34; Po0.001] and exposure to double therapy prior to initiating HAART (IRR 5 1.29; Po0.001) continued to be associated with increased rates of treatment change. Class of treatment combination also remained significantly associated with rates of change. Combinations that included a NNRTI, but not a PI, were associated with a slower rate of change than combinations that did not include a NNRTI (IRR 5 0.70; Po0.001); combinations that included both a NNRTI and a PI were associated with a faster rate of change than combinations that did not include a NNRTI (IRR 5 1.29; P 5 0.013); and mono or double therapies, and no therapy, were associated with increased rates of combination change (IRR 5 2.69; Po0.001 and IRR 5 1.26; P 5 0.002, respectively). During more recent time periods, particularly from 2001 onwards, the rates of combination change were also significantly slower compared with earlier years (Po0.001).
Post hoc analysis examined the association between ritonavir-boosted combinations and rates of treatment change. Combinations including stavudine and didanosine and their association with rates of change were also analysed. Results showed that treatment combinations that included ritonavir with at least one other PI did not differ significantly from other PI-containing regimens (P 5 0.92). However, combinations that included stavudine and/or didanosine demonstrated a significantly faster rate of treatment change compared with combinations excluding these two antiretrovirals (P 5 0.024).
Time to first treatment change
The median durations spent on first HAART combinations, by co-infection status, are shown in Fig. 1 . Overall, the median duration on first HAART combination was 482 days for those without HBV or HCV, 686 days for those with HBV alone, 398 days for those with HCV alone, and 172 days for those with HBV and HCV co-infection.
Time to first treatment change after commencing HAART was not significantly associated with co-infection status (P 5 0.51). The hazard ratios (HRs) from the Cox proportional hazard model for time to first treatment change after commencing HAART are presented in Table 3 . In univariate analysis, AIDS-defining illness prior to commencing HAART, and exposure to double therapy prior to commencing HAART, were associated with a faster time to first treatment change (P 5 0.041 and P 5 0.009, respectively). Combinations that included a NNRTI, but not a PI, were associated with a slower time to change than combinations that did not include a NNRTI (HR 5 0.63; Po0.001). Age, sex, HIV exposure category, CD4 at baseline, RNA at baseline, and year of first change were not significantly associated with time to first treatment change.
In multivariate analysis, exposure to double therapy prior to initiating HAART (HR 5 1.25; P 5 0.014) was found to be independently associated with a faster time to combination change. In addition, combinations that included a NNRTI, but not a PI, remained significantly associated with a slower time to change than combinations that did not include a NNRTI (HR 5 0.64; Po0.001).
Time to stopping nevirapine or efavirenz
Of the 805 patients who met the study inclusion criteria, 611 commenced a HAART combination that included nevirapine or efavirenz at some stage during the follow-up period. Overall, the median time between commencing and stopping either nevirapine or efavirenz was 1344 days. The median durations spent on treatments that included nevirapine or efavirenz, by co-infection status, are shown in Fig. 2 . Time to stopping nevirapine or efavirenz was not associated with hepatitis co-infection (P 5 0.86, Wilcoxon test).
Discussion
In the AHOD, the prevalences of HBV and HCV were 4.8% and 12.8%, respectively. Among the patients who were In this study, factors that were independently associated with an increased rate of change of combination antiretroviral treatment were a previous diagnosis with an AIDS-defining illness (34% faster), and prior exposure to double combination antiretroviral therapy compared with being previously naïve (29% faster). Combinations that included a NNRTI had a 30% slower rate of combination treatment change compared with combinations that included a PI. Co-infection with HBV and/or HCV was not found to be significantly associated with the rate of combination antiretroviral treatment change. Other factors, such as age, sex, exposure category, CD4 count and viral load at baseline, were also not significantly associated with the rate of combination antiretroviral treatment change. Although calendar year was significantly associated with the overall rate of combination change, it was not significantly associated with the first combination change. Co-infection status was also not associated with stopping treatment combinations that included either nevirapine or efavirenz.
Our findings that HBV and/or HCV co-infection was not associated with the rate of change of combination antiretroviral treatment are supported by several other studies. Greub et al. [8] found that the probability of changing antiretroviral treatment was not associated with HCV status, but was associated with AIDS at baseline, RNA at baseline, duration of therapy and sex. Sulkowski et al. [15] found that HCV co-infection did not alter virological or immunological response to HAART.
In our analysis, patients who were receiving a regimen including a NNRTI had a slower rate of change of antiretroviral treatment than those receiving a PI. Whether this was a result of better tolerability of these compounds or fewer adverse events, such as toxicities, is unknown. Calendar year was also shown to be associated with the rate of combination change overall, more recent time periods having significantly slower rates of change compared with earlier time periods. Such an association was not seen in time to first combination change post-HAART. This is probably a result of the fact that most patients in this cohort had commenced their very first HAART combination before the year 2000.
In the AHOD we also saw that co-infection status was not associated with stopping either nevirapine or efavirenz. In a study with similar demographics to the AHOD, where patients were predominantly homosexual men, no association was found between HBV and HCV infection and hepatotoxicity caused by NNRTI use [11] . Sulkowski et al. [10] analysed the outcome of NNRTI-containing HAART in an HIV hospital clinic and also found that the majority of their patients did not develop hepatotoxicity; however, among those who did, it was more common if they were also concurrently using a PI, or if they had HCV or HBC coinfection.
There are several limitations to our study. Firstly, recruitment to the AHOD commenced in June 1999, but a large proportion of the data concerning antiretroviral treatment, HIV disease stage, and HBV and HCV status was collected retrospectively. Hence, the analysis presented in this study is based on retrospective as well as prospective data. Secondly, HBV and HCV status data were not collected in a standardized format, but rather by clinician reporting. HCV status was based on antibody rather than HCV RNA testing, and HBV status, in some instances, may have been based on a single HBsAg antibody result. However, it could be expected that the large majority had chronic HBV and HCV infection. Among the HCV-infected patients, approximately 80% had chronic HCV infection based on the limited HCV RNA testing. Furthermore, no assessment of liver disease outcomes was conducted. Whether the study was sufficiently powered to detect a difference in the rates of change amongst the different coinfection groups is also questionable, given the wide confidence limits for each of these groups. A post hoc power analysis determined that at least 35 patients needed to be co-infected with HBV and HCV in order for the difference detected in this study to be significant. In this population, only 15 patients, less than half the required number, were co-infected with both HBV and HCV.
Finally, in this analysis it was not possible to assess whether treatment changes were caused by toxicity, virological failure or other factors. Ascribing reasons for treatment change is difficult, with toxicity, adherence and virological efficacy closely linked. A strength of our analysis is that all treatment changes were included, based on the assumption that more changes, for whatever reason, represent a poorer outcome than fewer changes. This overall rate of change endpoint is also quite a sensitive outcome [12] . Our analyses, both in this paper and in previous work [4] , suggest that HIV/HCV and HIV/HBV co-infection are not serious impediments to a patient's treatment for HIV infection. One feature of the HIV epidemic in Australia is that HIV transmission is overwhelmingly through male homosexual content, with very few people living with HIV actually injecting illicit drugs [16] . Whether the poorer outcomes, both in terms of response to treatment as well as in the long-term, as seen in co-infected patients in other studies, reflect ongoing active injecting drug use rather than HCV or HBV co-infection deserves more thorough investigation.
